x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Don"t Just Read the Abstract

Want to stay up-to-date on the very latest developments in non-malignant haematology? Don"t have the time or skills to critically appraise important papers? Join Pip and Rich, two haematology doctors on a journey of learning and discovery. Each episode, they will discuss a seminal trial, critically appraise the paper, interview a study author, and discuss the implications of the trial on clinical practice with a subject expert. CPD credits are available from RCPath. The podcast is sponsored by Sobi

health & fitness

All Episodes

43:19

ANNEXA-I: Discussion with Dr Will Lester

Don"t Just Read the Abstract ·

2024/10/02

In this episode, Pip and Rich discuss ANNEXA-I with Dr Will Lester, consultant haematologist at University Hospitals Birmingham. ANNEXA-I was a randomised controlled trial of andexanet alfa for reversal of anti-FXa oral anticoagulants in patients with intracerebral haemorrhage. There's a lot to get your teeth stuck into so and this one is a lively discussion!Disclosure: Pip and Rich are named investigators on a grant from AstraZeneca to audit the use of reversal agents (including andexanet) across

en

49:22

ANNEXA-I

Don"t Just Read the Abstract ·

2024/08/22

In this episode, Rich and Pip discuss the ANNEXA-I trial (https://www.nejm.org/doi/full/10.1056/NEJMoa2313040). This was a randomised controlled trial of andexanet alfa, a decoy factor Xa molecule that is a reversal agent for oral factor Xa inhibitors. Patients were randomised to andexanet alfa or usual care. The primary outcome was haemostatic efficacy and andexanet alfa was shown to result in better control of haematoma expansion compared to usual care. However, there are many discussion points

en

1:06:10

VITT, HIT, and spontaneous syndromes

Don"t Just Read the Abstract ·

2024/05/26

In this episode, Rich and Pip discuss vaccine-induced immune thrombotic thrombocytopenia and heparin-induced thrombocytopenia. They critique a recent paper that has shown that VITT has been around before vaccines against Covid-19. Importantly, they discuss which patients should be tested for spontaneous VITT- and HIT-like syndromes, and discuss a recent case. The paper is: Schönborn L. et al. Anti-PF4 immunothrombosis without proximate heparin or adenovirus vector vaccine exposure. Blood. 2023 Dec

en

1:02:58

Efgartigimod for ITP

Don"t Just Read the Abstract ·

2024/04/16

In this episode, Pip and Rich discuss the ADVANCE IV trial: Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia: a multicentre, randomised, placebo-controlled, phase 3 trial.With the help of Professor of Immunohaematology, Prof. Nikki Cooper, Rich and Pip dissect the trial, learning loads about ITP and the difficulties of doing trials in this space.Links: Broome C et al. Efficacy and safety of the neonatal Fc receptor inhibitor

en

1:29:58

FRAIL-AF

Don"t Just Read the Abstract ·

2024/03/04

In this episode, Pip and Rich discuss the FRAIL-AF study: Joosten et al. Safety of Switching From a Vitamin K Antagonist to a Non–Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial. Circulation. 2024;149:279–289.This trial randomised the switching of elderly frail patients who were established on a vitamin K antagonist to either remain on this treatment or switch to a direct oral anticoagulant. They found

en

1:06:54

The PACER trial

Don"t Just Read the Abstract ·

2024/01/21

In this, the first episode Drs Pip Nicolson and Rich Buka take a deep dive into the PACER trial: Platelet Transfusion before CVC Placement in Patients with Thrombocytopenia. After a quick round up of other trials that have sparked their interest, Pip and Rich discuss about the study aims and outcomes, before interviewing Dr Floor van Baarle, lead study author before discussing the clinical implications of the trial with Prof Simon Stanworth.Follow Pip, Rich, and HaemSTAR on X/Twitter: @PipNicolson,

en

26 results

Similar Podcasts

Доктор Тройняшкин

Доктор Тройняшкин

The Dry Eye Treatment PODCAST

Dry Eye Treatment

Différent et alors ?

PATRICK SULAY

Kyle Kingsbury Podcast

Kyle Kingsbury

The Real Weight Loss Coach

Matty Lansdown